AKT1 and neoplasm: These findings suggest that the combination of flubendazole and paclitaxel could affect microtubule dynamics, down-regulate HIF1α, and inhibit the PI3K/AKT signaling pathway, which results in synergistic anti-tumor effects for BC therapy.